Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DCTH | Tranche B warrants to purchase F-4 Preferred Stock | Options Exercise | $500K | +500 | $1,000.00 | 0 | Oct 30, 2024 | F-4 PREFERRED STOCK | 500 | $1,000.00 | By Rosalind Advisors, Inc., the advisor to the Rosalind Funds | F1, F2, F3 | |
transaction | DCTH | 8% CONVERTIBLE NOTE | Expiration (or cancellation) of long derivative position with value received | $0 | 0 | $0.00 | 0 | Oct 30, 2024 | CASH | $1.42M | $0.00 | By Rosalind Advisors, Inc., the advisor to the Rosalind Funds | F3, F4, F5 |
Id | Content |
---|---|
F1 | Immediately exercisable |
F2 | The Tranche B Warrants expire the earlier of (i) twenty-one (21) days following the date of the Issuer's public announcement of record at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and (ii) March 31, 2026. The Issuer announced on October 17, 2024 that it had recorded at least $10,000,000 in quarterly U.S. revenue from the commercialization of HEPZATO and therefore such Tranche B Warrants expire on November 7, 2024. |
F3 | Reporting Persons disclaims beneficial ownership over the shares except to the extent of his or its respective pecuniary interest therein |
F4 | N/A |
F5 | Delcath repaid the DELCATH SYSTEM - 8% CONVERTIBLE NOTE in full with cash of $1,423,333. |